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Cardiology Department, University of Athens Medical School, Hippokration General Hospital, Athens, GreecePericardial disorders constitute a relatively common cause of heart research. Recently, two more interventions have been added to the
disease accounting for 0.1–0.2% of all hospital admissions (Kytö et al.,
2014; Lange and Hillis, 2004). From a clinical point of view pericardial
syndromes encompass acute pericarditis (including relapses in the set-
ting of recurrent forms), chronic constrictive pericarditis and isolated
chronic pericardial effusion (Imazio and Adler, 2015).
With speciﬁc respect to etiology, idiopathic and secondary forms are
described, with the contribution of each form depending largely to the
local epidemiology (Lazaros et al., 2009). Namely, in the Western
world the great majority of acute pericarditis cases remain idiopathic
(presumably viral), with secondary forms accounting for ~15–20% of
the overall pericarditis cases (Imazio et al., 2010; Adler et al., 2015).
On the contrary, in developing countries the most common etiology of
acute pericarditis is tuberculous (TB) pericarditis. It represents 70–80%
of cases in immunocompetent patients in certain regions such as sub-
Saharan areas, rising to 90% in HIV-infected subjects (Imazio et al.,
2010; Adler et al., 2015). The relevant percentage in the Western
world is estimated at 4–5% (Imazio et al., 2010).
From all of the above, it is clear that in the diagnostic work-up in
pericarditis cases, the local epidemiology should be strongly considered.
However, in the speciﬁc context of TB, in recent years the high rates of
immigration from regions with high prevalence towards Western
Europe and North America, may alter local trends in acute pericarditis
etiology, a circumstance that physicians should be aware of (Imazio
et al., 2010).
TB pericarditis is a particular form of pericarditis for several reasons.
First, regarding prognosis, it is associated with a high short-term
mortality rates which approximates 16–40% in 6-month time period, a
rate which only in malignant pericardial disease may be recorded
(Mayosi et al., 2008; Lazaros and Stefanadis, 2013). Second, TB
pericarditis is among the forms of pericarditis with the fastest evolution
towards constrictive or effusive-constrictive forms. The rate of progres-
sion is 50% without treatment and it has been reduced to 17–40% upon
the introduction of effective TB chemotherapy, including rifampicin-
based treatment (Mayosi et al., 2008). Third, the most effective
treatment of TB pericarditis is still a subject of controversy and intensiveDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.09.034.
⁎ Corresponding author at: First Cardiology Department, University of Athens,
Hippokration Hospital, 114 Vas. Soﬁas Ave., 115 27 Athens, Greece.
E-mail address: glaz35@hotmail.com (G. Lazaros).
http://dx.doi.org/10.1016/j.ebiom.2015.10.009
2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article understandard therapeutic armamentarium of TB pericarditis, namely
intrapericardial urokinase and corticosteroid therapy (Adler et al.,
2015; Mayosi et al., 2008). The efﬁcacy and safety of corticosteroid ad-
ministration has been debated at length. This issue has been recently
addressed in the IMPI trial, which included 1400 patients with either
deﬁnite or possible pericarditis (Mayosi et al., 2008). The main ﬁndings
of this trial were that although corticosteroids did not have a signiﬁcant
impact on the prespeciﬁed composite end point (including death, cardi-
ac tamponade associated with hemodynamic compromise and chronic
constrictive pericarditis development), prednisolone administration
for six months resulted in a lower incidence of constrictive pericarditis
and a need for hospitalization. Nevertheless, steroid administration
resulted in a higher incidence of cancer mainly driven by an increase
in HIV-associated cancer. Thus, corticosteroid administration should
be reserved exclusively for immunocompetent patients.
Last but not the least, the diagnosis of TB pericarditis is a challenging
issue. Current diagnostic criteria consider the diagnosis of TB pericardi-
tis deﬁnite, in the presence of tubercle bacilli in biopsy specimens of
pericardial tissue or in the pericardial ﬂuid as detected by polymerase
chain reaction or culture (Adler et al., 2015). Cases are considered
possible in patients with unexplained pericarditis and either
extrapericardial tuberculosis or elevated levels of adenosine deaminase,
lysozyme and unstimulated interferon-gamma levels (any among
them). A successful response to chemotherapy regimens in endemic
areas constitutes an additional criterion. We emphasize that deﬁnite
cases in the IMPI trial accounted for only 17% of the cases (Mayosi
et al., 2008).
Although intense and high quality research focused on TB pericardi-
tis has been accomplished in recent years, additional investigation is
well-acknowledged. In particular, issues concerning diagnosis and
treatment are required in the setting of both basic and clinical research.
In this line, the paper published in this issue of the journal by
Pasipanodya JG, is welcomed as a study that provides new and impor-
tant insights at basic and clinical level (Pasipanodya et al., 2015). This
investigation enrolled 70 patients with conﬁrmed TB pericarditis
included in the IMPI registry. The key messages of this study are
summarized in three main ﬁndings.
The ﬁrst ﬁnding is that even in the era of highly effective TB chemo-
therapy (namely the regimen used in the IMPI trial), the mortality of TB
pericarditis is still high, with an overall mortality rate of 1.43 perthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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plausible explanation for this ﬁnding derived from a highly adherent
population, is the inadequate antibiotic concentrations in thepericardial
ﬂuid (especially rifampin and pyrazinamide), due to poor penetration
(Shenje et al., 2015). Moreover, since severe immunosuppression was
an independent predictor of death, deprivation of the inherent immune
system defensive mechanisms offers an additional explanation.
The second ﬁnding and important novelty of this investigation, is
that deﬁnite TB pericarditis may not constitute a paucibacillary disease
as previously suggested. Thus, improvement on methodology to detect
bacterial burden in the pericardial ﬂuid is of paramount importance in
order to improve diagnostic accuracy.
Finally, the third ﬁnding is that bacillary burden outranks well-
established mortality predictors such as hypotension, constrictive
pericarditis and effusive constrictive pericarditis. Accordingly, in an
effort to reduce bacterial load, the administration of rapidly acting
bactericidal drugs is particularly important for disease control.
In summary, TB pericarditis is a major cause of morbidity andmortal-
ity especially, but not exclusively, in developing countries. Additional
research is urgently required to ensure an evidence-based approach of
tackling the disease. In an effort to put all of these ﬁndings into perspec-
tive, of high priority in our treatment decisions should be the prompt
reduction of the bacillary load, in order to prevent morbidity andmortal-
ity. Additional efforts should include preventive measures towards HIV
infection spread. Administration of alternative chemotherapeutic regi-
mens ensuring higher intrapericardial concentrations or modiﬁcations
of the standard ones (concerning dosage and administration period),
are prerequisites to put together the challenging puzzle of TB pericarditis.Conﬂict of interest
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